Pharmaceuticals, Biotechnology and Life Sciences
Merck is Contributing 300,000 Masks to New Jersey’s Office of Homeland Security and Preparedness to Support COVID-19 Relief Efforts KENILWORTH,…
Merck said on Tuesday it got top-line efficacy results from two its pivotal Phase 3 trials (COUGH-1 and COUGH-2) testing…
Merck said Monday that it iwll, through a subsidiary, initiate a tender offer to acquire all outstanding shares of ArQule for nearly $2.7 billion, or for $20 per share in cash.
4D pharma Wednesday said that its clinical study with Merck to test MRx0518 combined with Keytruda further support its continued investment into our oncology franchise.
Merck has received positive EU CHMP opinion for two new regimens of Keytruda (pembrolizumab) as first-line ttreatment for metastatic or…
Merck has received EU CHMP positive opinion for investigational V920 ebola Zaire vaccine for protection Against ebola virus disease.
Merck has issued its corporate responsibility report, illustrating its approach to long-Term sustainability for business and society.
Nevakar, ophthalmology specialist pharmaceutical company has entered into a $17.5 million product financing agreement with an affiliate of H.I.G. Capital Partners, L.P. for the continued development of five differentiated, sterile injectable products.
KENILWORTH, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Michael Nally,…
Merck’s trial of Keytruda plus chemotherapy, followed by adjuvant Keytruda as monotherapy, which was granted Breakthrough Therapy designation (BTD) by the U.S. Food and Drug Administration (FDA) for the neoadjuvant treatment of patients with high-risk, early-stage TNBC plus chemotherapy, resulted in a statistically significant increase in pathological complete response (pCR) versus chemotherapy.